New drug duo aims to shrink prostate tumors before surgery

NCT ID NCT05938270

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study tests two drugs, saruparib and darolutamide, given alone or together before prostate removal surgery in men with newly diagnosed prostate cancer. The goal is to see how these drugs affect cancer cells and check for side effects. About 120 men with localized, higher-risk prostate cancer will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Research Site

Detroit, Michigan, 48202, United States
Research Site

Providence, Rhode Island, 02903, United States
Research Site

Melbourne, VIC 3000, Australia
Research Site

South Brisbane, 4101, Australia
Research Site

Vancouver, British Columbia, V5Z 1M9, Canada
Research Site

Toronto, Ontario, M5G 2M9, Canada
Research Site

Québec, Quebec, G1J 1Z4, Canada
Research Site

Amsterdam, 1066CX, Netherlands
Research Site

Nijmegen, 6525 GA, Netherlands
Research Site

Barcelona, 08036, Spain
Research Site

Barcelona, 8035, Spain
Research Site

Madrid, 28041, Spain
Research Site

Valencia, 46009, Spain
Research Site

Cambridge, CB2 0QQ, United Kingdom
Research Site

Manchester, M20 4BX, United Kingdom
Research Site

Newcastle upon Tyne, NE7 7AF, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.